Pharmaceuticals, Biotechnology and Life Sciences
Presented three abstracts at American Society of Gene & Cell Therapy (“ASGCT”) demonstrating early proof-of-concept data across multiple gene editing…
• New data confirm highly selective profile of cell-targeted lipid nanoparticle (ctLNP) and first-ever siRNA delivery to T cells in…
Topline results for RAPIDe-3, a pivotal Phase 3 study of deucrictibant for the on-demand treatment of HAE attacks, expected in…
– Presented and published the positive results from both the Launch-HTN and Advance-HTN pivotal trials at scientific meetings and in…
TORONTO, Aug. 11, 2025 (GLOBE NEWSWIRE) — Revive Therapeutics Ltd. (“Revive” or the “Company”) (OTCQB: RVVTF) (CSE: RVV) (FRANKFURT: 31R),…
The Phase 1b program is designed to evaluate the clinical activity of NXP900 as a single agent in patients with…
HUNTSVILLE, Aug. 11, 2025 (GLOBE NEWSWIRE) — Serina Therapeutics, Inc. (“Serina”) (NYSE American: SER), a clinical-stage biotechnology company advancing its…
Business combination transaction with Helix Acquisition Corp. II, a special purpose acquisition company sponsored by affiliates of Cormorant Asset Management,…
Woburn, MA, Aug. 11, 2025 (GLOBE NEWSWIRE) — Biofrontera Inc. (Nasdaq: BFRI) (the “Company”), a biopharmaceutical company focused on the…
$5.0 million upfront with up to an additional $12.5 million of potential aggregate gross proceeds upon the exercise in full…